Vetoquinol SA (EPA:VETO)

France flag France · Delayed Price · Currency is EUR
77.30
+1.10 (1.44%)
Sep 26, 2025, 5:35 PM CET
1.44%
Market Cap911.81M
Revenue (ttm)532.39M
Net Income (ttm)59.96M
Shares Out11.80M
EPS (ttm)5.10
PE Ratio15.17
Forward PE14.57
Dividend0.89 (1.15%)
Ex-Dividend DateJun 4, 2025
Volume2,616
Average Volume6,620
Open76.80
Previous Close76.20
Day's Range76.80 - 78.00
52-Week Range63.60 - 87.70
Beta0.74
RSI53.27
Earnings DateSep 11, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, pigs, dogs, and cats. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of S... [Read more]

Sector Healthcare
Founded 1933
Employees 2,501
Stock Exchange Euronext Paris
Ticker Symbol VETO
Full Company Profile

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial Statements

News